Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $74.74 USD
Change Today +0.28 / 0.38%
Volume 883.0K
STJ On Other Exchanges
New York
As of 8:04 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (STJ) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/23/15 - $75.73
52 Week Low
10/16/14 - $54.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ST JUDE MEDICAL INC (STJ)

st jude medical inc (STJ) Related Businessweek News

View More BusinessWeek News

st jude medical inc (STJ) Details

St. Jude Medical, Inc., together with its subsidiaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems and cardiac resynchronization therapy defibrillator devices to treat patients suffering from lethal heart conditions, such as sudden cardiac arrest or heart failure. It also provides pacemakers, which deliver low-voltage electrical impulses to stimulate a heartbeat for patients whose hearts beat too slowly; and atrial fibrillation products comprising electrophysiology, introducers and catheters, advanced cardiac mapping, navigation and recording systems, and ablation systems. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, percutaneous catheter introducers, diagnostic guidewires, renal denervation technology and vascular plugs, optical coherence tomography imaging products, and other vascular accessories, as well as CardioMEMS, a heart failure monitoring device. Further, it provides structural heart products, including transcatheter aortic heart valves, various surgical heart valve repair and replacement products, and transcatheter structural heart defect devices; and neuromodulation products, such as spinal cord stimulation and radiofrequency ablation to treat chronic pain, as well as deep brain stimulation to treat movement disorders. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in St. Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/15
Founded in 1976

st jude medical inc (STJ) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Vice President of...
Total Annual Compensation: $468.8K
Chief Operating Officer
Total Annual Compensation: $788.3K
President of International Division
Total Annual Compensation: $752.4K
Group President
Total Annual Compensation: $708.5K
Compensation as of Fiscal Year 2014.

st jude medical inc (STJ) Key Developments

St. Jude Medical Inc. Announces New Results from Two Clinical Studies Adds Evidence Supporting Use of St. Jude Medical Fractional Flow Reserve Technology

St. Jude Medical Inc. announced that new results from two clinical studies further supporting the use of St. Jude Medical fractional flow reserve (FFR) technology to optimize percutaneous coronary intervention (PCI) procedures used to restore blood flow to the heart. The studies – a 15-year follow-up to the DEFER study and primary results from the CONTRAST study – were presented earlier during hotline sessions at EuroPCR 2015. Combined, the studies contribute to the growing body of evidence supporting FFR as a valuable and important decision-making tool for physicians. St. Jude Medical’s PressureWire FFR technology supports better treatment decisions for patients by providing a more detailed, physiologic analysis of blood flow blockages in the heart. Specifically, FFR can help accurately identify which coronary lesions or blockages are responsible for obstructing the flow of blood to a patient’s heart muscle. This insight allows physicians to determine which lesions warrant stenting, resulting in improved patient outcomes and reduced health care costs. In a 15-year follow up study, new data from the DEFER study confirms original and five-year findings. Researchers leading the DEFER study found the positive benefits of decisions based on St. Jude Medical PressureWire FFR guidance were sustained after 15 years. The study also found the risk for a myocardial infarction was 6.5 times lower in patients where treatment was guided by FFR compared to patients in the non-FFR guided group, while finding no negative effect of leaving non-significant lesions untreated. The DEFER study’s 15 year data is an important advancement of FFR, because it confirms sustained benefits of FFR guidance over time. After 15 years, DEFER researchers found stenting a non-ischemic stenosis, or narrowing of the blood vessel restricting blood flow to the heart, had no benefit compared to patients treated by standard medical therapy. In addition to a reduction in heart attacks, patients where revascularization was deferred had very low rates of complications compared to patients in which lesions were treated without proof of ischemia. In the CONTRAST study, researchers assessed FFR differently, and compared the gold standard in vascular physiologic assessment, FFR using adenosine, to resting indices (Pd/Pa and iFR) and a new approach to adenosine-free FFR; FFR using contrast medium. Contrast FFR (cFFR), also known as contrast Pd/Pa, is a new diagnostic approach where the hyperemic effect (an increase in blood flow) is induced by contrast medium in place of adenosine. The study found that cFFR provides superior accuracy compared to resting indices such as iFR or resting Pd/Pa. To date, simplifying physiologic assessment using resting indices has resulted in a reduction in accuracy, which has limited adoption. The CONTRAST study found both Pd/Pa and iFR to offer similar rates of accuracy. In addition, the study’s researchers concluded cFFR did not add extra cost or procedure time and may be a viable option for situations where the use of adenosine is undesired or contra indicated.

St. Jude Medical Announces Canadian Launch and First Implant of the Prodigy Spinal Cord Stimulation System with Burst Stimulation

St. Jude Medical Inc. announced Health Canada approval and first implant in Canada of its Prodigy Chronic Pain System with Burst technology. The Prodigy system is the only implantable spinal cord stimulation (SCS) system approved to deliver St. Jude Medical’s proprietary Burst stimulation as well as traditional SCS to reduce pain, improve patient satisfaction and eliminate paresthesia, the tingling sensation commonly associated with traditional SCS, in some patients. A 52-year-old man from Saskatoon, received the Prodigy neurostimulator on May 13 due to his experience with chronic pain for several years following a successful trial experience and was performed by Dr. Ivar Mendez, M.D., Ph.D, FRCSC, FACS, from Saskatoon Health Region’s Royal University Hospital in Saskatchewan, Canada. SCS therapy uses an implanted pulse generator and thin wires with electrodes to deliver low levels of electrical energy to nerve fibers. These electrical pulses mask or interrupt pain signals as they travel to the brain, reducing the sensation of pain. Traditional tonic stimulation uses equally spaced electrical pulses to replace pain with a tingling sensation called paresthesia. For some patients, the stimulation sensation can fluctuate with changes in body position and paresthesia may become uncomfortable. St. Jude Medical’s Burst stimulation works differently, and offers intermittent “bursts” of stimulation, designed to mimic the human body’s natural design of neuron signaling and thus provide an alternative therapy method for chronic pain conditions. In addition, Burst stimulation has been shown to significantly reduce or eliminate paresthesia. The ability to support two modes of stimulation provides clinicians with the opportunity to more effectively adjust the therapy to a patient’s unique pain condition and may be especially helpful over time. The Prodigy system features the longest-lasting battery life of all rechargeable SCS devices approved for use in Canada and, unlike some competitive devices, does not include a manufacturer-induced device shut-off. Additionally, its small size allows for a smaller incision, which gives physicians increased flexibility in selecting the implant location and is intended to make the site less visible and more comfortable for patients. Through an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA), the St. Jude Medical study called SUNBURST (Success Using Neuromodulation with BURST) is evaluating whether Burst stimulation can be more effective in managing chronic pain than traditional tonic stimulation. The Prodigy neurostimulator is not approved for use in the U.S.

St. Jude Medical Inc. Expands Portfolio of MRI-Compatible Devices to High Voltage in Europe

St. Jude Medical Inc. announced CE Mark approval of expanded labelling for its Ellipse™ implantable cardioverter defibrillator (ICD), in addition to its Durata™ and Optisure™ defibrillation leads, allowing existing or future patients with these technologies to undergo magnetic resonance imaging (MRI) scans without compromising device performance. The company also announced that it has received CE Mark approval for its Assurity MRI™ and Endurity MRI™ pacemaker device families. The approvals further expand St. Jude Medical’s MRI-conditional device portfolio in Europe. Designed to offer patients added protection in the event of a life-threatening arrhythmia, the Ellipse device is among the smallest and most advanced ICDs. The device uses the company’s DynamicTx™ algorithm, which automatically adjusts shocking configurations for patients in order to ensure the delivery of high-voltage therapy if an electrical short occurs in one part of the system. The Ellipse ICD also utilizes DeFT Response™ technology, allowing for physicians to customize the amount of energy delivered for each individual patient, in addition to low friction coating on the device can. The added coating has been demonstrated in testing to significantly reduce the friction between the device and leads, potentially reducing lead-to-can abrasion, which is one of the most common types of insulation failure in the industry. The Assurity MRI and Endurity MRI devices are the world’s smallest, longest-lasting wireless pacemakers available to patients. These devices allow early notification of atrial fibrillation-related events and pacing that helps reduce heart failure-related hospitalizations. Both pacemakers are supported by the™ Patient Care Network (PCN) website for remote patient management. In the coming months, St. Jude Medical anticipates updated labeling for many of its existing cardiac rhythm management devices, which will allow more patients the ability to safely undergo MRI scans. St. Jude Medical is planning to submit test data in key markets around the world in 2015 for MRI conditional labeling on additional existing high-voltage products including the Fortify™ Assura ICD, Quadra Assura CRT-D, and quarter LV leads.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $74.74 USD +0.28

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.87 USD -0.11
CR Bard Inc $172.38 USD -0.66
Olympus Corp ¥4,215 JPY -40.00
Smith & Nephew PLC 1,135 GBp -5.00
Zimmer Holdings Inc $114.46 USD +0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation STJ Industry Range
Price/Earnings 21.2x
Price/Sales 3.8x
Price/Book 5.4x
Price/Cash Flow 18.9x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at